Tabelecleucel in the treatment of EBV+ PTLD

(3:16)

Dr. Prockop Discusses Tabelecleucel in Post-Transplant EBV+ Lymphomas

(1:18)

Tabelecleucel in EBV-associated PTLD

(2:59)

Tabelecleucel as an alternative treatment option in patients following transplantation

(2:35)

Update on ALLELE: tab-cel in patients with EBV+ PTLD following alloSCT after rituximab failure

(6:1econd)

The treatment and management of PTLD

(2:24)

Strategies for the management of EBV-PTLD

(1:56)

Tab-cel for solid organ or allogeneic transplant recipients with EBV-PTLD

(2:21)

Atara Biotherapeutics

(14:37)

Promising therapeutic efficacy of EBV-specific T-cell immunotherapy tabelecleucel in PTLD

(5:42)

Long-term outcomes of subjects with EBV driven PTLD following solid organ or allogeneic HCT trea...

(10:47)

Emerging therapies for EBV-driven PTLD \u0026 insights into the ALLELE trial

(2:23)

Clinical outcomes of patients with EBV-PTLD who fail rituximab following HSCT

(1:58)

ATA 188 for Multiple Sclerosis (anti-EBV neurogenic t-cell therapy from Atara Biotherapeutics)

(13:38)

The current landscape of allogeneic CAR T-cell therapies

(3:9)

Advances in EBV-PTLD

(2:26)

ASCO 2022 | Pr Sylvain Choquet, le tabelecleucel, une thérapie cellulaire innovante

(1:58)

“I want to know how to heal chronically active EBV\

(20:32)